CLDN4 and colorectal carcinoma: It has been shown that combination treatment with 5-fluorouracil (FU) and an anti-CLDN4 extracellular domain antibody (4D3) enhances antitumor efficacy against CRC (Fujiwara-Tani et al., 2018).